九典制药
(300705)
| 流通市值：45.41亿 | | | 总市值：61.59亿 |
| 流通股本：3.69亿 | | | 总股本：5.00亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 595,244,012.8 | 3,110,900,254.23 | 2,268,037,308.7 | 1,511,949,503.84 |
| 营业收入 | 595,244,012.8 | 3,110,900,254.23 | 2,268,037,308.7 | 1,511,949,503.84 |
| 二、营业总成本 | 540,618,256.72 | 2,579,938,093.88 | 1,835,670,058.22 | 1,196,892,509.26 |
| 营业成本 | 197,350,304.42 | 841,683,507.07 | 578,944,690.44 | 384,340,563.5 |
| 税金及附加 | 7,548,072.72 | 36,793,852.15 | 27,396,744.15 | 18,108,326.44 |
| 销售费用 | 240,255,334.09 | 1,305,742,567 | 956,737,649.64 | 610,422,295.01 |
| 管理费用 | 54,701,336.59 | 164,525,622.72 | 89,902,249.25 | 54,202,211.99 |
| 研发费用 | 34,194,794.02 | 218,409,582.01 | 174,151,080.41 | 124,839,091.23 |
| 财务费用 | 6,568,414.88 | 12,782,962.93 | 8,537,644.33 | 4,980,021.09 |
| 其中:利息费用 | 6,638,372.45 | 14,994,107.28 | 10,433,335.49 | 6,482,654.98 |
| 其中:利息收入 | 270,575.27 | 2,464,617.62 | 1,989,892.25 | 1,467,467.13 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -445,930.62 | -955,602.86 | -344,033.52 | 226,199.83 |
| 资产处置收益 | 0 | 50,728.92 | 48,150.68 | 0 |
| 资产减值损失(新) | -1,806,873.86 | -30,849,329.66 | -2,506,475.13 | -3,301,213.35 |
| 信用减值损失(新) | 33,862.47 | -905,610.14 | -62,752.81 | -657,376.73 |
| 其他收益 | 8,696,397.34 | 39,440,115.5 | 29,385,210.34 | 18,354,840.85 |
| 四、营业利润 | 61,103,211.41 | 537,742,462.11 | 458,887,350.04 | 329,679,445.18 |
| 加:营业外收入 | 458,596.55 | 2,106,576.26 | 2,072,712.84 | 277,697.58 |
| 减:营业外支出 | 533,298.75 | 13,488,039.16 | 8,280,784.56 | 4,378,336.83 |
| 五、利润总额 | 61,028,509.21 | 526,360,999.21 | 452,679,278.32 | 325,578,805.93 |
| 减:所得税费用 | 6,766,246.81 | 56,325,565.77 | 46,317,276.22 | 34,155,596.98 |
| 六、净利润 | 54,262,262.4 | 470,035,433.44 | 406,362,002.1 | 291,423,208.95 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 54,262,262.4 | 470,035,433.44 | 406,362,002.1 | 291,423,208.95 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 56,736,098.14 | 472,818,048.51 | 406,362,543.64 | 291,423,208.95 |
| 少数股东损益 | -2,473,835.74 | -2,782,615.07 | -541.54 | 0 |
| 扣除非经常损益后的净利润 | 50,597,232.2 | 453,129,305.84 | 391,016,726.94 | 282,781,130.52 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.11 | 0.96 | 0.82 | 0.59 |
| (二)稀释每股收益 | 0.11 | 0.95 | 0.79 | 0.58 |
| 九、综合收益总额 | 54,262,262.4 | 470,035,433.44 | 406,362,002.1 | 291,423,208.95 |
| 归属于母公司股东的综合收益总额 | 56,736,098.14 | 472,818,048.51 | 406,362,543.64 | 291,423,208.95 |
| 归属于少数股东的综合收益总额 | -2,473,835.74 | -2,782,615.07 | -541.54 | 0 |
| 公告日期 | 2026-04-25 | 2026-04-25 | 2025-10-30 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |